ever, for equity financings for companies such as Helix is challenging, and there can be no assurance that additional funding by way of equity financing will be available. The failure of the Company to obtain additional funding on a timely basis may result in the Company reducing, delaying or cancelling one or more of its planned research, development and marketing programs and reducing related personnel, any of which could impair the current and future value of the business. Any additional equity financing, if secured, may result in significant dilution to the existing shareholders at the time of such financing. The Company may also seek additional funding from other sources, including technology licensing, co-development collaborations, and other strategic alliances, which, if obtained, may reduce the Company's interest in its projects or products. There can be no assurance, however, that any alternative sources of funding will be available.
The Company's unaudited interim consolidated balance sheet as at April 30, 2009, and audited consolidated balance sheet as at July 31, 2008, are summarized below:
Consolidated Balance Sheets as at
($ thousands)
30-Apr 31-Jul 30-Apr 31-Jul
2009 2008 2009 2008
Current assets: Current liabilities:
Cash and cash
equivalents 19,598 19,057 Accounts payable 2,351 598
Accounts receivable 452 349 Accrued liabilities 308 546
Inventory 822 458 2,659 1,144
Prepaid and other 482 446
21,354 20,310
Non current assets 1,584 1,356 Shareholders'
equity 20,279 20,522
22,938 21,666 22,938 21,666
'/>"/>
SOURCE Helix BioPharma Corp. Copyright©2009 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Related biology technology :1.
Helix Biopharma announces addition of University of Arizona professor Kenneth Hatch as new medical advisor2.
Helix BioPharma Chairman resigns3.
Helix BioPharma Corp. announces fiscal 2007 results4.
Helix BioPharma Corp. announces management changes5.
Helix BioPharma announces $16.9 million private placement of common shares6.
Helix BioPharma announces Q1 2008 financial results7.
Helix BioPharma closes $16.9 million private placement of common shares8.
Helix BioPharma Corp. contracts KBI Biopharma to develop an L-DOS47 clinical packaging format9.
Helix BioPharma shareholders vote in favour of management10.
Helix BioPharma reports Q2 2008 highlights, financial results11.
W. Thomas Hodgson appointed to board of Helix BioPharma Corp.